Evolus
EOLS
104 hedge funds and large institutions have $133M invested in Evolus in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 36 increasing their positions, 29 reducing their positions, and 25 closing their positions.
48% more call options, than puts
Call options by funds: $3.04M | Put options by funds: $2.06M
24% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 29
4.72% more ownership
Funds ownership: 32.3% → 37.02% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $135M → $133M (-$1.67M)
8% less funds holding
Funds holding: 113 → 104 (-9)
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
Top Buyers
Top Sellers
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$4.27M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$2.29M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.95M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.83M |
| 5 |
Millennium Management
New York
|
-$1.42M |
EOLS Hedge Fund Activity: Q4 2021 in Review
104 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Evolus (EOLS) for Q4 2021, worth a combined $133M — down 1.2% from $135M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of EOLS and 18 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 36 added.
The largest buyer was Stonepine Capital Management, adding an estimated $10.7M. The largest seller was Maven Securities, exiting entirely with an estimated $4.27M sold.
- 104 institutional investors held Evolus (EOLS) as of Q4 2021, down from 113 in Q3 2021.
- Funds reported $133M of Evolus stock for Q4 2021, down 1.2% quarter-over-quarter.
- 18 funds opened new Evolus positions in Q4 2021 and 25 closed out, a net change of -7 holders.
- The largest Evolus buyer in Q4 2021 was Stonepine Capital Management, an estimated $10.7M added.
- The largest Evolus seller in Q4 2021 was Maven Securities, an estimated $4.27M sold.
Based on aggregated 13F filings for Q4 2021.